SBIR/STTR Research Award

DIAGNOSTIC TEST FOR PERIODONTAL BONE LOSS

Award identifier ce12c6ca0be9648e9b0ba93957a873c9e29031b53decb7d56291fdba27762e93Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$181,946

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOMIMETIC PHARMACEUTICALS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Periodontitis is the leading cause of tooth loss in adults. A major limitation in the clinical management of patients susceptible to periodontal disease is the inability to detect active alveolar bone loss. Currently, the clinician diagnoses periodontitis based upon historical measures such as radiographs and probing pocket depths. The major shortcoming of using these measures is that they do not predict future disease activity. Recent advances in the diagnosis of metabolic skeletal disorders have lead to the investigation of biomarkers of periodontal alveolar bone loss. A class of bone collagen degradative by-products termed pyridinoline crosslinks (Pyds) are promising indicators of active bone resorption. We have demonstrated that Pyds have great potential as diagnostic aids for periodontal and pen-implant bone loss. To date, there is no simple method to detect Pyds in patients with periodontitis. In our research plan we propose the development of a test that can provide a "real-time" assessment of periodontal disease activity. Our Specific Aims in this Phase I application are: 1) to develop a rapid "chairside" immunoassay for the detection of Pyds (both deoxypyridinoline (Dpd) and C-telopeptide pyridinoline crosslink of Type I Collagen (ICTP)); and 2) to determine the ability of the chairside diagnostic test to discriminate between periodontal health and periodontitis cross-sectionally. This Phase I investigation if successful would lead to a Phase II application that would apply this rapid test to determine the diagnostic ability of Pyds to predict oral bone loss in a multicenter longitudinal study of patients susceptible to periodontal disease.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.